167 related articles for article (PubMed ID: 31397806)
1. Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics.
Jordan SC; Ammerman N; Vo A
Transplantation; 2020 Jan; 104(1):17-23. PubMed ID: 31397806
[TBL] [Abstract][Full Text] [Related]
2. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
3. Research progress on neonatal Fc receptor and its application.
Hu M; Wei S; Zhou W; Wang P
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 50(4):537-544. PubMed ID: 34704415
[TBL] [Abstract][Full Text] [Related]
4. Targeting neonatal Fc receptor: potential clinical applications in pregnancy.
Moise KJ; Oepkes D; Lopriore E; Bredius RGM
Ultrasound Obstet Gynecol; 2022 Aug; 60(2):167-175. PubMed ID: 35229965
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic age of the neonatal Fc receptor.
Pyzik M; Kozicky LK; Gandhi AK; Blumberg RS
Nat Rev Immunol; 2023 Jul; 23(7):415-432. PubMed ID: 36726033
[TBL] [Abstract][Full Text] [Related]
6. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals.
Baldwin WM; Valujskikh A; Fairchild RL
Am J Transplant; 2019 Jul; 19(7):1881-1887. PubMed ID: 30903736
[TBL] [Abstract][Full Text] [Related]
7. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
8. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.
Challa DK; Velmurugan R; Ober RJ; Sally Ward E
Curr Top Microbiol Immunol; 2014; 382():249-72. PubMed ID: 25116104
[TBL] [Abstract][Full Text] [Related]
9. Neonatal Fc receptor and IgG-based therapeutics.
Kuo TT; Aveson VG
MAbs; 2011; 3(5):422-30. PubMed ID: 22048693
[TBL] [Abstract][Full Text] [Related]
10. Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport.
Stapleton NM; Armstrong-Fisher SS; Andersen JT; van der Schoot CE; Porter C; Page KR; Falconer D; de Haas M; Williamson LM; Clark MR; Vidarsson G; Armour KL
Mol Immunol; 2018 Mar; 95():1-9. PubMed ID: 29367080
[TBL] [Abstract][Full Text] [Related]
11. The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik M; Sand KMK; Hubbard JJ; Andersen JT; Sandlie I; Blumberg RS
Front Immunol; 2019; 10():1540. PubMed ID: 31354709
[TBL] [Abstract][Full Text] [Related]
12. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
13. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
14. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.
Sockolosky JT; Szoka FC
Adv Drug Deliv Rev; 2015 Aug; 91():109-24. PubMed ID: 25703189
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.
Sivadasan A; Bril V
Immunotherapy; 2023 Jun; 15(8):553-563. PubMed ID: 37013835
[TBL] [Abstract][Full Text] [Related]
16. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
[TBL] [Abstract][Full Text] [Related]
17. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.
Rath T; Baker K; Dumont JA; Peters RT; Jiang H; Qiao SW; Lencer WI; Pierce GF; Blumberg RS
Crit Rev Biotechnol; 2015 Jun; 35(2):235-54. PubMed ID: 24156398
[TBL] [Abstract][Full Text] [Related]
18. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
19. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.
Peter HH; Ochs HD; Cunningham-Rundles C; Vinh DC; Kiessling P; Greve B; Jolles S
J Allergy Clin Immunol; 2020 Sep; 146(3):479-491.e5. PubMed ID: 32896308
[TBL] [Abstract][Full Text] [Related]
20. FcRn: the neonatal Fc receptor comes of age.
Roopenian DC; Akilesh S
Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
